Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

Preliminary data from an ongoing Phase 2 trial evaluating satraplatin plus Taxol(R) (paclitaxel) in the first-line treatment of patients with advanced non-small cell lung cancer were also published in the ASCO educational book (Shipley, D. et al. Phase II trial of satraplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer). Data from 24 patients were available for analysis; a total of approximately 40 patients are expected to be enrolled in the study. This preliminary analysis showed that satraplatin plus Taxol appears to have activity in this treatment setting. In an effort to reduce myelosuppression in the study, the satraplatin dose has been lowered to 70 mg/m2 from 80 mg/m2. The study continues to enroll and follow patients.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an oral compound that clinical trial patients are able to take at home. Satraplatin is not currently approved by the FDA in the United States, by the EMEA in the European Union or any other regulatory authority and no conclusions can or should be drawn regarding its safety and efficacy.

A Phase 3 registrational trial, called SPARC, is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone- refractory prostate cancer whose prior chemotherapy has failed. Data from the trial on progression-free survival and on safety have been presented at recent medical conferences.

GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories.
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:12/4/2009)FREMONT, Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) announced that on December 3, 2009, it filed its First Amended Plan of Reorganization and related amended Disclosure Statement wit
(Date:12/4/2009)OMAHA, Neb., Dec. 4 Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services. For nearly 15 years,
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
Breaking Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Amber Pharmacy Earns Accreditation From ACHC 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Judge Halts IHSS Home Care Cuts 3B Says They Likely Violate Federal Law 59781 1Judge Halts IHSS Home Care Cuts 3B Says They Likely Violate Federal Law 59781 2Narconon of Georgia Applauds Efforts of Prescription Buy Back Programs 5577 1Narconon of Georgia Applauds Efforts of Prescription Buy Back Programs 5577 2Researcher honored for experimental work in nanotechnology 14533 1Researcher honored for experimental work in nanotechnology 14533 2
... April 11, 2007 (PRIME NEWSWIRE) --,Hana Bioscienc...sed,on advancing cancer care, will present preclin...ion at the American Association,for Cancer Researc...geles, California. , Abstract No. 2210: "Combining...mall cell lung cancer (NSCLC) athymic nude,mice xe...
...onex Inc. (TSX:LPX), a,biopharmaceutical company s...d to High Density Lipoprotein (HDL), often called,...om further,analysis of the Phase I/II Clinical Tri...ped for the treatment of dyslipidemia and,heart di...indicated that all,blood chemistry and blood press...
Other Medicine Technology:Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting 2Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting 3Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data 2Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data 3
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2
...procedures are generally being fleased from patien...ne of California, observed a study at present whic...sary fertility procedures.// Lawrence Werlin,...gnosis (PGD) for three distinct groups of women. P...
...n pointed at reducing carbon monoxide emissions ha...onoxide can be fatal if inhaled and is involved in...ear. //The main sources of carbon monoxide are veh...talytic converters in cars helps bring down the ca...
...to researchers, it may be possible to increase the...shortage of organs for transplantation.// Research...ng at the supply of lungs for transplant. They not...hecked 30 pairs of lungs that had been rejected fo...
...to researchers in England, a baby's birth weight i...late adulthood. The study also shows women with th...risk of developing diabetes.// More than 4,10...ing among those with the highest insulin resistanc...
...rs at the Colulmbia University found that eating m...eloping Alzheimer's disease in some people. Previo...ricted diet tend to live longer. //Researchers fee...lso damage cells and may increase the damage done ...
...antioxidants have always been beneficial to our bo...tent is released from the grain, and thereby makin...e has always been a common misconception that boil...ou may well gain more antioxidant power than you l...
Other Medicine News:Health News:Diet combined to Alzheimer's disease 2
... Clear Plus™ Uncuffed Endotracheal Tube w. F...et inside. Sterile, Single use. A quality Rusch en... is ready to use saving you time and storage space...ate smooth withdrawal. It is designed with a soft ...
Slick Set® Uncuffed
Cuffed Nasoral Magill
...ubber tube with Murphy eye. Laser resistant foam s...uffs (One inside other) 40cm (16") long, Single Us...access and optimum visibility within the operating...he tube shaft has a special laser-guard of approx....
Medicine Products: